Kantonsspital St.Gallen
login

publications

Markus Joerger

title  
 
Jung S, Valmaggia C, Joerger M, Todorova M. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients. Klin Monbl Augenheilkd. 2021; 238:403-409.
   
Baldauf M, Kapauer M, Joerger M, Flatz L, Frank S, Felbecker A, Hundsberger T. Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. Neurol Neuroimmunol Neuroinflamm 2021; 8:.
   
Bösch M, Baty F, Rothschild S I, Tamm M, Joerger M, Früh M, Brutsche M. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021;.
   
Hamzic S, Aebi S, Joerger M, Montemurro M, Ansari M, Amstutz U, Largiadèr C. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss Med Wkly 2020; 150:w20375.
   
Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen S L W, Mathijssen R H J, Joerger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. Front Pharmacol 2020; 11:283.
   
Mueller-Schoell A, Klopp-Schulze L, Schroth W, Mürdter T, Michelet R, Brauch H, Huisinga W, Joerger M, Neven P, Koolen S L W, Mathijssen R H J, Copson E, Eccles D, Chen S, Chowbay B, Tfayli A, Zgheib N K, Schwab M, Kloft C. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clin Pharmacol Ther 2020; 108:661-670.
   
Schaerer D, Froehlich T K, Hamzic S, Offer S M, Diasio R B, Joerger M, Amstutz U, Largiadèr C R. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. J Pers Med 2020; 10:.
   
Muth M, Ojara F W, Kloft C, Joerger M. Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol 2020; 87:306-316.
   
Gachechiladze M, Škarda J, Skanderová D, Überall I, Kolek V, Smičkova P, Vojta P, Vbrková J, Hajdúch M, Shani I, Kolář Z, Stahel R, Weder W, Rulle U, Soltermann A, Joerger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. Lung Cancer 2020; 147:30-38.
   
Ojara F W, Henrich A, Frances N, Huisinga W, Hartung N, Joerger M, Kloft C. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. J Pharmacol Exp Ther 2020; 375:430-438.
   
Gachechiladze M, Škarda J, Bouchalova K, Soltermann A, Joerger M. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors. Front Oncol 2020; 10:581217.
   
Joerger M, Stathis A, Metaxas Y, Hess D, Mantiero M, Mark M, Volden M, Kaindl T, Engelhardt M, Larger P, Lane H, Hafner P, Levy N, Stuedeli S, Sessa C, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Invest New Drugs 2019;.
   
van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung W K A, Wen P Y, Lassman A B, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin O A, Zhang H, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019;.
   
Hurkmans D P, Basak E A, van Dijk T, Mercieca D, Schreurs M W J, Wijkhuijs A J M, Bins S, Hoop E O D, Debets R, Joerger M, Odink A, van der Veldt A A M, van der Leest C H, Aerts J G J V, Mathijssen R H J, Koolen S L W. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019; 7:192.
   
Herbrand A K, Schmitt A M, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord K A, Novak U, Sricharoenchai S, Hemkens L G, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
   
Hamzic S, Kummer D, Froehlich T K, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens J H M, García-González X, López-Fernández L A, Amstutz U, Largiadèr C R. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
   
O'Brien O, Wright M C, O'Brien C, Geoghegan O, Leonard N, Nicholson S, Cuffe S, Fabre A, Jochum W, Joerger M, Gray S G, Finn S P. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. Diagnostics (Basel) 2019; 9:.
   
Crombag M R B S, Koolen S L W, Wijngaard S, Joerger M, Dorlo T P C, van Erp N P, Mathijssen R H J, Beijnen J H, Huitema A D R. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. Pharm Res 2019; 36:163.
   
Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, ring s, Niederer R, Gil Cruz C, Perez Shibayama C, Krolik M, siano m, Joerger M, Recher M, Risch L, guesewell s, Risch M, Speiser D E, Ludewig B, Levesque M P, Dummer R, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
   
Schuler M, Cho B C, Sayehli C M, Navarro A, Soo R A, Richly H, Cassier P A, Tai D, Penel N, Nogova L, Park S H, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019;.
   
Schett A, Rothschild S I, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
   
Heinhuis K M, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J P, Paz-Ares L, Britschgi C, Schilder R J, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu L L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2019;1-8.
   
Joerger M, gueller u, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol 2019; 10:373-378.
   
Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou A M, Ma C, Hurvitz S A, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel) 2019; 11:.
   
Überall I, Gachechiladze M, Joerger M, Anděl J, Smičková P, Kolek V, Grygárková I, Škarda J. Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer. Lung Cancer 2019; 129:85-91.
   
Crombag M R B S, de Vries Schultink A H M, Koolen S L W, Wijngaard S, Joerger M, Schellens J H M, Dorlo T P C, van Erp N P, Mathijssen R H J, Beijnen J H, Huitema A D R. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharm Res 2019; 36:33.
   
Joerger M. [Molecularly-targeted anticancer treatments - a short appraisal]. Ther Umsch 2019; 76:179-185.
   
Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné A S, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé V O, Van Calster B, Guchelaar H J. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clin Cancer Res 2018; 24:2312-2318.
   
siano m, Jarisch N, Joerger M, Espeli V. Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. Anticancer Res 2018; 38:3725-3729.
   
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
   
Klopp-Schulze L, Joerger M, Wicha S G, Ter Heine R, Csajka C, Parra-Guillen Z P, Kloft C. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clin Pharmacokinet 2018; 57:229-242.
   
Beumer J H, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim T W, Mathijssen R H, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 2018;.
   
siano m, Espeli V, Joerger M. Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer. Tumori 2018;300891618811276.
   
Behrend H, Lengnick H, Zdravkovic V, Ladurner A, Rudin D, Erschbamer M, Joerger M, Kuster M. Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study. Knee Surg Sports Traumatol Arthrosc 2018;.
   
Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
   
Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann C J, Allegrini S, Catapano C V, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C, Swiss Group for Clinical Cancer Research (SAKK) . Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
   
Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader C R. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017; 102:796-804.
   
Gachechiladze M, Škarda J, Kolek V, Grygárková I, Langová K, Bouchal J, Kolář Z, Baty F, Stahel R, Weder W, Soltermann A, Joerger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer 2017; 105:31-38.
   
Gachechiladze M, Škarda J, Soltermann A, Joerger M. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. Int J Cancer 2017; 141:1286-1294.
   
Parra-Guillen Z P, Berger P B, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, gillessen s, Krähenbühl S, Kloft C, Joerger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
   
Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z P. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362:347-358.
   
Joerger M, Kraff S, Jaehde U, Hilger R A, Courtney J B, Cline D J, Jog S, Baburina I, Miller M C, Salamone S J. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit 2017; 39:617-624.
   
Klopp-Schulze L, Joerger M, Wicha S G, Parra-Guillen Z P, Kloft C. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
. Int J Clin Pharmacol Ther 2016;.
   
Warschkow R, cerny t, Schmied B, gueller u, Thürlimann B, Joerger M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.
   
Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, cerny t, Joerger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
   
Warschkow R, gueller u, Tarantino I, cerny t, Schmied B, Thürlimann B, Joerger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.
   
Hager S, Ackermann C J, Joerger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016; 27:975-84.
   
Baty F, Joerger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016; 11:S81.
   
Crombag M R B S, Joerger M, Thürlimann B, Schellens J H M, Beijnen J H, Huitema A D R. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8:.
   
Joerger M, Finn S P, Cuffe S, Byrne A T, Gray S G. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opin Ther Targets 2016; 20:1339-1356.
   
Shao S, Guo T, Gross V, Lazarev A, Koh C C, gillessen s, Joerger M, Jochum W, Aebersold R. Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. J Proteome Res 2016; 15:1821-9.
   
Meulendijks D, Rozeman E A, Cats A, Sikorska K, Joerger M, Deenen M J, Beijnen J H, Schellens J H M. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J 2016;.
   
Hamzic S, Wenger N, Froehlich T K, Joerger M, Aebi S, Largiadèr C R, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016;.
   
Joerger M, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp H G, Behringer D M, Ko Y D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.
   
Shao S, Guo T, Koh C C, gillessen s, Joerger M, Jochum W, Aebersold R. Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry. Proteomics 2015; 15:3711-21.
   
Joerger M, van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, gillessen s, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 2015;.
   
Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, cerny t, Beijnen J H, Schellens J H M. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
   
Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft H S, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey U J M. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
   
Kraff S, Nieuweboer A J M, Mathijssen R H J, Baty F, de Graan A J, van Schaik R H N, Jaehde U, Joerger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015;.
   
Guo T, Kouvonen P, Koh C C, Gillet L C, Wolski W E, Röst H L, Rosenberger G, Collins B C, Blum L C, gillessen s, Joerger M, Jochum W, Aebersold R. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 2015; 21:407-13.
   
Joerger M, Baty F, Früh M, Droege C, Stahel R A, Betticher D C, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
   
Froehlich T K, Amstutz U, Aebi S, Joerger M, Largiadèr C R. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
   
Joerger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2014;1-12.
   
Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
   
Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.
   
Früh M, Besrour H, gillessen s, Joerger M, Hitz F, Savidan A, cerny t, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013; 59:42-50.
   
Büchel B, Sistonen J, Joerger M, Aebi Y, Schürch S, Largiadèr C R. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clin Chem Lab Med 2013; 51:1681-8.
   
Joerger M. [Role of individualized dosing in oncology: are we there yet?]. Praxis (Bern 1994) 2013; 103:33-9.
   
Joerger M, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz F, cerny t, Schellens J H M, gillessen s. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013; 73:113-24.
   
Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 2012; 14:119-32.
   
Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.
   
Joerger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Ann Oncol 2012; 22:567-574.
   
Büchel B, Joerger M, Schürch S, Largiader C. Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy. Biomed Chromatogr 2012;.
   
Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clin Breast Cancer 2012; 12:102-9.
   
Büchel B, Joerger M, Schürch S, Largiader C. Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities. 2012; Clinical Chemistry Annual Conference:.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
   
Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.
   
Joerger M, Kraff S, Huitema A D R, Feiss G, Moritz B, Schellens J H M, Beijnen J H, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-17.
   
Joerger M, Huitema A D R, Illerhaus G, Ferreri A J M. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 2012; 53:1867-75.
   
hochstrasser a, Benz G, Joerger M, templeton a, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
   
Joerger M, Ferreri A J M, Krähenbühl S, Schellens J H M, cerny t, Zucca E, Huitema A D R. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
   
Joerger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012; 192:197-223.
   
Joerger M, Wilkins J, Fagagnini S, Baldinger R, Brenneisen R, Schneider U, Goldman B, Weber M. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett 2012; 6:102-8.
   
Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 2011; 15:65-71.
   
Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clin Breast Cancer 2011;.
   
adamina m, Joerger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-211.
   
Joerger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-11.
   
Joerger M, Burgers J A, Baas P, Doodeman V D, Smits P H M, Jansen R S, Vainchtein L D, Rosing H, Huitema A D R, Beijnen J H, Schellens J H M. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
   
Joerger M, Huitema A D R, Illerhaus G, Ferreri A J M. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. Leuk Lymphoma 2011; 52:1825-7.
   
Joerger M, Burgers S A, Baas P, Smit E F, Haitjema T J, Bard M P L, Doodeman V D, Smits P H M, Vincent A, Huitema A D R, Beijnen J H, Schellens J H M. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.
   
Joerger M, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R, Beijnen J H, Schellens J H M. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.
   
Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010; 2:293-301.
   
Joerger M, Riesen W F, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010;.
   
Joerger M, Huitema A D R, Krähenbühl S, Schellens J H M, cerny t, Reni M, Zucca E, Cavalli F, Ferreri A J M. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
   
Buikhuisen W A, Burgers J A, Vincent A D, Schellens J H M, Beijnen J H, Smit E F, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010; 28:e482-3; author reply e484.
   
Joerger M, Omlin A, cerny t, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
   
Joerger M, templeton a, koeberle d, Engler H, Riesen W F, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010;.
   
Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.
   
Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
   
 
page 1 of 2